ID   NMDE1_RAT               Reviewed;        1464 AA.
AC   Q00959; O08948; Q63728;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   02-OCT-2024, entry version 213.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 2A {ECO:0000305};
DE            Short=GluN2A {ECO:0000303|PubMed:27618671};
DE   AltName: Full=Glutamate [NMDA] receptor subunit epsilon-1;
DE   AltName: Full=N-methyl D-aspartate receptor subtype 2A;
DE            Short=NMDAR2A {ECO:0000303|PubMed:8428958};
DE            Short=NR2A {ECO:0000303|PubMed:1350383, ECO:0000303|PubMed:9509416};
DE   Flags: Precursor;
GN   Name=Grin2a {ECO:0000312|RGD:2737};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=1350383; DOI=10.1126/science.256.5060.1217;
RA   Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H.,
RA   Burnashev N., Sakmann B., Seeburg P.H.;
RT   "Heteromeric NMDA receptors: molecular and functional distinction of
RT   subtypes.";
RL   Science 256:1217-1221(1992).
RN   [2]
RP   SEQUENCE REVISION TO 595 AND 597-598.
RA   Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H.,
RA   Burnashev N., Sakmann B., Seeburg P.H.;
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT, FUNCTION, AND SUBCELLULAR LOCATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Forebrain;
RX   PubMed=8428958; DOI=10.1016/s0021-9258(18)53849-7;
RA   Ishii T., Moriyoshi K., Sugihara H., Sakurada K., Kadotani H., Yokoi M.,
RA   Akazawa C., Shigemoto R., Mizuno N., Masu M., Nakanishi S.;
RT   "Molecular characterization of the family of the N-methyl-D-aspartate
RT   receptor subunits.";
RL   J. Biol. Chem. 268:2836-2843(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RA   Boulter J.;
RT   "Nucleotide sequence of rat NMDA receptor gene NMDAR2A.";
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH DLG4.
RX   PubMed=7569905; DOI=10.1126/science.7569905;
RA   Kornau H.C., Schenker L.T., Kennedy M.B., Seeburg P.H.;
RT   "Domain interaction between NMDA receptor subunits and the postsynaptic
RT   density protein PSD-95.";
RL   Science 269:1737-1740(1995).
RN   [6]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9509416;
RA   Jin D.H., Jung Y.W., Ko B.H., Moon I.S.;
RT   "Immunoblot analyses on the differential distribution of NR2A and NR2B
RT   subunits in the adult rat brain.";
RL   Mol. Cells 7:749-754(1997).
RN   [7]
RP   INTERACTION WITH AIP1.
RX   PubMed=9694864; DOI=10.1074/jbc.273.33.21105;
RA   Hirao K., Hata Y., Ide N., Takeuchi M., Irie M., Yao I., Deguchi M.,
RA   Toyoda A., Suedhof T.C., Takai Y.;
RT   "A novel multiple PDZ domain-containing molecule interacting with N-methyl-
RT   d-aspartate receptors and neuronal cell adhesion proteins.";
RL   J. Biol. Chem. 273:21105-21110(1998).
RN   [8]
RP   INTERACTION WITH PATJ.
RX   PubMed=9647694; DOI=10.1006/mcne.1998.0679;
RA   Kurschner C., Mermelstein P.G., Holden W.T., Surmeier D.J.;
RT   "CIPP, a novel multivalent PDZ domain protein, selectively interacts with
RT   Kir4.0 family members, NMDA receptor subunits, neurexins, and
RT   neuroligins.";
RL   Mol. Cell. Neurosci. 11:161-172(1998).
RN   [9]
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION IN A COMPLEX WITH GRIN1 AND
RP   GRIN3A.
RX   PubMed=11160393; DOI=10.1523/jneurosci.21-04-01228.2001;
RA   Perez-Otano I., Schulteis C.T., Contractor A., Lipton S.A., Trimmer J.S.,
RA   Sucher N.J., Heinemann S.F.;
RT   "Assembly with the NR1 subunit is required for surface expression of NR3A-
RT   containing NMDA receptors.";
RL   J. Neurosci. 21:1228-1237(2001).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1; GRIN3A AND PPP2CB.
RX   PubMed=11588171; DOI=10.1523/jneurosci.21-20-07985.2001;
RA   Chan S.F., Sucher N.J.;
RT   "An NMDA receptor signaling complex with protein phosphatase 2A.";
RL   J. Neurosci. 21:7985-7992(2001).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=12391275; DOI=10.1124/mol.62.5.1119;
RA   Al-Hallaq R.A., Jarabek B.R., Fu Z., Vicini S., Wolfe B.B., Yasuda R.P.;
RT   "Association of NR3A with the N-methyl-D-aspartate receptor NR1 and NR2
RT   subunits.";
RL   Mol. Pharmacol. 62:1119-1127(2002).
RN   [12]
RP   IDENTIFICATION IN A COMPLEX WITH GRIN1 AND GRIN3A.
RX   PubMed=11929923; DOI=10.1152/jn.00531.2001;
RA   Sasaki Y.F., Rothe T., Premkumar L.S., Das S., Cui J., Talantova M.V.,
RA   Wong H.-K., Gong X., Chan S.F., Zhang D., Nakanishi N., Sucher N.J.,
RA   Lipton S.A.;
RT   "Characterization and comparison of the NR3A subunit of the NMDA receptor
RT   in recombinant systems and primary cortical neurons.";
RL   J. Neurophysiol. 87:2052-2063(2002).
RN   [13]
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION IN A COMPLEX WITH GRIN1 AND
RP   GRIN3B.
RX   PubMed=14602821; DOI=10.1523/jneurosci.23-31-10064.2003;
RA   Matsuda K., Fletcher M., Kamiya Y., Yuzaki M.;
RT   "Specific assembly with the NMDA receptor 3B subunit controls surface
RT   expression and calcium permeability of NMDA receptors.";
RL   J. Neurosci. 23:10064-10073(2003).
RN   [14]
RP   INTERACTION WITH LRFN2.
RX   PubMed=16495444; DOI=10.1523/jneurosci.3799-05.2006;
RA   Wang C.Y., Chang K., Petralia R.S., Wang Y.X., Seabold G.K., Wenthold R.J.;
RT   "A novel family of adhesion-like molecules that interacts with the NMDA
RT   receptor.";
RL   J. Neurosci. 26:2174-2183(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-882; SER-890; SER-929;
RP   SER-1025; SER-1059; SER-1062; SER-1198 AND SER-1291, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [16]
RP   FUNCTION, INTERACTION WITH RPH3A AND DLG4, AND SUBCELLULAR LOCATION.
RX   PubMed=26679993; DOI=10.1038/ncomms10181;
RA   Stanic J., Carta M., Eberini I., Pelucchi S., Marcello E., Genazzani A.A.,
RA   Racca C., Mulle C., Di Luca M., Gardoni F.;
RT   "Rabphilin 3A retains NMDA receptors at synaptic sites through interaction
RT   with GluN2A/PSD-95 complex.";
RL   Nat. Commun. 6:10181-10181(2015).
RN   [17]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=22960932; DOI=10.1038/nn.3214;
RA   Rodenas-Ruano A., Chavez A.E., Cossio M.J., Castillo P.E., Zukin R.S.;
RT   "REST-dependent epigenetic remodeling promotes the developmental switch in
RT   synaptic NMDA receptors.";
RL   Nat. Neurosci. 15:1382-1390(2012).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=28384476; DOI=10.1016/j.neuron.2017.03.018;
RA   Sun W., Hansen K.B., Jahr C.E.;
RT   "Allosteric Interactions between NMDA Receptor Subunits Shape the
RT   Developmental Shift in Channel Properties.";
RL   Neuron 94:58-64(2017).
RN   [19]
RP   INTERACTION WITH ARC.
RX   PubMed=31080121; DOI=10.1016/j.str.2019.04.001;
RA   Nielsen L.D., Pedersen C.P., Erlendsson S., Teilum K.;
RT   "The capsid domain of Arc changes its oligomerization propensity through
RT   direct interaction with the NMDA receptor.";
RL   Structure 0:0-0(2019).
RN   [20] {ECO:0007744|PDB:2A5S, ECO:0007744|PDB:2A5T}
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 402-539 AND 661-802 IN COMPLEXES
RP   WITH GRIN1 AND GLUTAMATE, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, DOMAIN,
RP   AND DISULFIDE BOND.
RX   PubMed=16281028; DOI=10.1038/nature04089;
RA   Furukawa H., Singh S.K., Mancusso R., Gouaux E.;
RT   "Subunit arrangement and function in NMDA receptors.";
RL   Nature 438:185-192(2005).
RN   [21] {ECO:0007744|PDB:4JWX}
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 402-539 AND 661-802 IN COMPLEX
RP   WITH SYNTHETIC AGONIST, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   DISULFIDE BONDS.
RX   PubMed=23625947; DOI=10.1124/mol.113.085803;
RA   Hansen K.B., Tajima N., Risgaard R., Perszyk R.E., Jorgensen L.,
RA   Vance K.M., Ogden K.K., Clausen R.P., Furukawa H., Traynelis S.F.;
RT   "Structural determinants of agonist efficacy at the glutamate binding site
RT   of N-methyl-D-aspartate receptors.";
RL   Mol. Pharmacol. 84:114-127(2013).
RN   [22] {ECO:0007744|PDB:4NF4, ECO:0007744|PDB:4NF5, ECO:0007744|PDB:4NF6, ECO:0007744|PDB:4NF8}
RP   X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 402-539 AND 661-802 IN COMPLEXES
RP   WITH GRIN1 AND GLUTAMATE, FUNCTION, SUBUNIT, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF PHE-416; TYR-730 AND VAL-734.
RX   PubMed=24462099; DOI=10.1016/j.neuron.2013.11.033;
RA   Jespersen A., Tajima N., Fernandez-Cuervo G., Garnier-Amblard E.C.,
RA   Furukawa H.;
RT   "Structural insights into competitive antagonism in NMDA receptors.";
RL   Neuron 81:366-378(2014).
RN   [23] {ECO:0007744|PDB:5I56, ECO:0007744|PDB:5I57, ECO:0007744|PDB:5I58, ECO:0007744|PDB:5I59, ECO:0007744|PDB:5JTY}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 402-539 AND 661-800 IN COMPLEX
RP   WITH GRIN1 AND GLUTAMATE, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND
RP   DISULFIDE BONDS.
RX   PubMed=27618671; DOI=10.1016/j.neuron.2016.08.014;
RA   Yi F., Mou T.C., Dorsett K.N., Volkmann R.A., Menniti F.S., Sprang S.R.,
RA   Hansen K.B.;
RT   "Structural Basis for Negative Allosteric Modulation of GluN2A-Containing
RT   NMDA Receptors.";
RL   Neuron 91:1316-1329(2016).
RN   [24] {ECO:0007744|PDB:5TPW, ECO:0007744|PDB:5TQ0, ECO:0007744|PDB:5TQ2}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 34-393 IN COMPLEX WITH GRIN1 AND
RP   ZINC, FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, SUBUNIT,
RP   MUTAGENESIS OF LYS-233; ASN-264 AND ASP-282, AND DISULFIDE BONDS.
RX   PubMed=27916457; DOI=10.1016/j.neuron.2016.11.006;
RA   Romero-Hernandez A., Simorowski N., Karakas E., Furukawa H.;
RT   "Molecular Basis for Subtype Specificity and High-Affinity Zinc Inhibition
RT   in the GluN1-GluN2A NMDA Receptor Amino-Terminal Domain.";
RL   Neuron 92:1324-1336(2016).
RN   [25] {ECO:0007744|PDB:5U8C}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 402-539 AND 661-802 IN COMPLEX
RP   WITH GRIN1 AND SYNTHETIC ANTAGONIST, FUNCTION, SUBCELLULAR LOCATION,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=28468946; DOI=10.1124/mol.116.107912;
RA   Romero-Hernandez A., Furukawa H.;
RT   "Novel Mode of Antagonist Binding in NMDA Receptors Revealed by the Crystal
RT   Structure of the GluN1-GluN2A Ligand-Binding Domain Complexed to NVP-
RT   AAM077.";
RL   Mol. Pharmacol. 92:22-29(2017).
RN   [26] {ECO:0007744|PDB:5DEX, ECO:0007744|PDB:5VIH, ECO:0007744|PDB:5VIJ}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 402-539 AND 566-800 IN COMPLEX
RP   WITH GRIN1, FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND DISULFIDE BONDS.
RX   PubMed=28760974; DOI=10.1073/pnas.1707752114;
RA   Lind G.E., Mou T.C., Tamborini L., Pomper M.G., De Micheli C., Conti P.,
RA   Pinto A., Hansen K.B.;
RT   "Structural basis of subunit selectivity for competitive NMDA receptor
RT   antagonists with preference for GluN2A over GluN2B subunits.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E6942-E6951(2017).
RN   [27] {ECO:0007744|PDB:5VII}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 402-539 AND 566-800 IN COMPLEX
RP   WITH GRIN1, SUBUNIT, AND DISULFIDE BONDS.
RA   Mou T.C., Sprang S.R., Hansen K.B.;
RT   "Crystal structure of GluN1/GluN2A NMDA receptor agonist binding domains
RT   with glycine and antagonist, phenyl-ACEPC.";
RL   Submitted (APR-2017) to the PDB data bank.
CC   -!- FUNCTION: Component of NMDA receptor complexes that function as
CC       heterotetrameric, ligand-gated ion channels with high calcium
CC       permeability and voltage-dependent sensitivity to magnesium. Channel
CC       activation requires binding of the neurotransmitter glutamate to the
CC       epsilon subunit, glycine binding to the zeta subunit, plus membrane
CC       depolarization to eliminate channel inhibition by Mg(2+). Sensitivity
CC       to glutamate and channel kinetics depend on the subunit composition;
CC       channels containing GRIN1 and GRIN2A have lower sensitivity to
CC       glutamate and faster deactivation kinetics than channels formed by
CC       GRIN1 and GRIN2B (PubMed:28384476). Contributes to the slow phase of
CC       excitatory postsynaptic current, long-term synaptic potentiation, and
CC       learning (By similarity). Participates in the synaptic plasticity
CC       regulation through activation by the L-glutamate releaseed by BEST1,
CC       into the synaptic cleft, upon F2R/PAR-1 activation in astrocyte (By
CC       similarity). {ECO:0000250|UniProtKB:P35436, ECO:0000269|PubMed:1350383,
CC       ECO:0000269|PubMed:16281028, ECO:0000269|PubMed:23625947,
CC       ECO:0000269|PubMed:24462099, ECO:0000269|PubMed:26679993,
CC       ECO:0000269|PubMed:27618671, ECO:0000269|PubMed:27916457,
CC       ECO:0000269|PubMed:28384476, ECO:0000269|PubMed:28468946,
CC       ECO:0000269|PubMed:28760974, ECO:0000269|PubMed:8428958}.
CC   -!- ACTIVITY REGULATION: Channel activity is inhibited by nM concentrations
CC       of Zn(2+). {ECO:0000269|PubMed:27916457}.
CC   -!- SUBUNIT: Heterotetramer. Forms heterotetrameric channels composed of
CC       two zeta subunits (GRIN1), and two epsilon subunits (GRIN2A, GRIN2B,
CC       GRIN2C or GRIN2D) (in vitro) (PubMed:1350383, PubMed:8428958,
CC       PubMed:28384476, PubMed:16281028, PubMed:23625947, PubMed:24462099,
CC       PubMed:27618671, PubMed:27916457, PubMed:28468946, PubMed:28760974,
CC       Ref.27). Can also form heterotetrameric channels that contain at least
CC       one zeta subunit (GRIN1), at least one epsilon subunit, plus GRIN3A or
CC       GRIN3B (PubMed:11160393, PubMed:11588171, PubMed:12391275,
CC       PubMed:11929923). In vivo, the subunit composition may depend on the
CC       expression levels of the different subunits (Probable). Found in a
CC       complex with GRIN1, GRIN3A and PPP2CB (PubMed:11588171). Found in a
CC       complex with GRIN1 and GRIN3B (PubMed:14602821). Interacts with AIP1
CC       (PubMed:9694864). Interacts with HIP1 and NETO1. Interacts with SNX27
CC       (via PDZ domain); the interaction is required for recycling to the
CC       plasma membrane when endocytosed and prevent degradation in lysosomes
CC       (By similarity). Interacts with PDZ domains of PATJ and DLG4
CC       (PubMed:7569905, PubMed:9647694). Interacts with LRFN2
CC       (PubMed:16495444). Interacts with RPH3A and DLG4; this ternary complex
CC       regulates NMDA receptor composition at postsynaptic membranes
CC       (PubMed:26679993). Interacts with SORCS2 (By similarity). Interacts
CC       with ARC; preventing ARC oligomerization (PubMed:31080121). Interacts
CC       (via the extreme C-terminus) with FRMPD2 (the second PDZ domain); the
CC       interaction is direct and is likely to promote NMDAR-mediated neural
CC       signal transmission (By similarity). GRIN2A binds FRMPD2 with lower
CC       affinity than GRIN2B (By similarity). {ECO:0000250|UniProtKB:P35436,
CC       ECO:0000269|PubMed:11160393, ECO:0000269|PubMed:11588171,
CC       ECO:0000269|PubMed:11929923, ECO:0000269|PubMed:12391275,
CC       ECO:0000269|PubMed:1350383, ECO:0000269|PubMed:14602821,
CC       ECO:0000269|PubMed:16281028, ECO:0000269|PubMed:16495444,
CC       ECO:0000269|PubMed:23625947, ECO:0000269|PubMed:24462099,
CC       ECO:0000269|PubMed:26679993, ECO:0000269|PubMed:27618671,
CC       ECO:0000269|PubMed:27916457, ECO:0000269|PubMed:28384476,
CC       ECO:0000269|PubMed:28468946, ECO:0000269|PubMed:28760974,
CC       ECO:0000269|PubMed:31080121, ECO:0000269|PubMed:7569905,
CC       ECO:0000269|PubMed:8428958, ECO:0000269|PubMed:9647694,
CC       ECO:0000269|PubMed:9694864, ECO:0000269|Ref.27, ECO:0000305}.
CC   -!- INTERACTION:
CC       Q00959; P31016: Dlg4; NbExp=5; IntAct=EBI-630970, EBI-375655;
CC       Q00959; Q8R4I7: Neto1; Xeno; NbExp=4; IntAct=EBI-630970, EBI-2314926;
CC       Q00959; P05480: Src; Xeno; NbExp=4; IntAct=EBI-630970, EBI-298680;
CC   -!- SUBCELLULAR LOCATION: Cell projection, dendritic spine
CC       {ECO:0000269|PubMed:26679993}. Cell membrane
CC       {ECO:0000269|PubMed:11160393, ECO:0000269|PubMed:1350383,
CC       ECO:0000269|PubMed:14602821, ECO:0000269|PubMed:16281028,
CC       ECO:0000269|PubMed:23625947, ECO:0000269|PubMed:24462099,
CC       ECO:0000269|PubMed:27618671, ECO:0000269|PubMed:27916457,
CC       ECO:0000269|PubMed:28384476, ECO:0000269|PubMed:28468946,
CC       ECO:0000269|PubMed:28760974, ECO:0000269|PubMed:8428958}; Multi-pass
CC       membrane protein {ECO:0000305}. Synapse {ECO:0000250|UniProtKB:P35436}.
CC       Postsynaptic cell membrane {ECO:0000269|PubMed:26679993,
CC       ECO:0000269|PubMed:9509416}; Multi-pass membrane protein {ECO:0000305}.
CC       Cytoplasmic vesicle membrane {ECO:0000250|UniProtKB:P35436}.
CC       Note=Expression at the dendrite cell membrane and at synapses is
CC       regulated by SORCS2 and the retromer complex.
CC       {ECO:0000250|UniProtKB:P35436}.
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex, olfactory bulb,
CC       hippocampus including the dentate gyrus, striatum, thalamus, superior
CC       colliculus, inferior colliculus, midbrain and cerebellum (at protein
CC       level) (PubMed:22960932, PubMed:9509416). Detected in brain cortex,
CC       hypothalamus and cerebellum (PubMed:1350383).
CC       {ECO:0000269|PubMed:1350383, ECO:0000269|PubMed:22960932,
CC       ECO:0000269|PubMed:9509416}.
CC   -!- DEVELOPMENTAL STAGE: Expressed during postnatal days P3 to P60, with
CC       increased expression after postnatal day 3.
CC       {ECO:0000269|PubMed:22960932}.
CC   -!- DOMAIN: Contains an N-terminal domain, a ligand-binding domain and a
CC       transmembrane domain. Agonist binding to the extracellular ligand-
CC       binding domains triggers channel gating. {ECO:0000305|PubMed:16281028}.
CC   -!- DOMAIN: A hydrophobic region that gives rise to the prediction of a
CC       transmembrane span does not cross the membrane, but is part of a
CC       discontinuously helical region that dips into the membrane and is
CC       probably part of the pore and of the selectivity filter.
CC       {ECO:0000250|UniProtKB:B7ZSK1}.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel (TC 1.A.10.1)
CC       family. NR2A/GRIN2A subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M91561; AAC03565.1; -; mRNA.
DR   EMBL; D13211; BAA02498.1; -; mRNA.
DR   EMBL; AF001423; AAB58801.1; -; mRNA.
DR   PIR; A43274; A43274.
DR   RefSeq; NP_036705.3; NM_012573.3.
DR   PDB; 2A5S; X-ray; 1.70 A; A=401-539.
DR   PDB; 2A5T; X-ray; 2.00 A; B=401-539.
DR   PDB; 4JWX; X-ray; 1.50 A; A=404-539, A=661-802.
DR   PDB; 4NF4; X-ray; 2.00 A; B=402-539, B=661-802.
DR   PDB; 4NF5; X-ray; 1.90 A; B=402-539, B=661-802.
DR   PDB; 4NF6; X-ray; 2.10 A; B=402-539, B=661-802.
DR   PDB; 4NF8; X-ray; 1.86 A; B=402-539, B=661-802.
DR   PDB; 5DEX; X-ray; 2.40 A; B=402-539, B=661-802.
DR   PDB; 5I56; X-ray; 2.28 A; B=402-539, B=661-800.
DR   PDB; 5I57; X-ray; 1.70 A; B=402-539, B=661-800.
DR   PDB; 5I58; X-ray; 2.52 A; B=402-539, B=661-800.
DR   PDB; 5I59; X-ray; 2.25 A; B=402-539, B=661-800.
DR   PDB; 5JTY; X-ray; 2.72 A; B=402-539, B=661-800.
DR   PDB; 5TPW; X-ray; 2.91 A; B=34-393.
DR   PDB; 5TQ0; X-ray; 2.70 A; B=34-393.
DR   PDB; 5TQ2; X-ray; 3.29 A; B=34-393.
DR   PDB; 5U8C; X-ray; 1.60 A; B=402-539, A=661-802.
DR   PDB; 5VIH; X-ray; 2.40 A; B=402-539, B=566-800.
DR   PDB; 5VII; X-ray; 1.95 A; B=402-539, B=566-800.
DR   PDB; 5VIJ; X-ray; 2.10 A; B=402-539, B=566-800.
DR   PDB; 6MM9; EM; 5.97 A; B/D=1-837.
DR   PDB; 6MMA; EM; 6.31 A; B/D=1-837.
DR   PDB; 6MMB; EM; 12.70 A; B/D=1-837.
DR   PDB; 6MMG; EM; 6.23 A; B/D=1-837.
DR   PDB; 6MMH; EM; 8.21 A; B/D=1-837.
DR   PDB; 6MMI; EM; 8.93 A; B/D=1-837.
DR   PDB; 6MMJ; EM; 16.50 A; B/D=1-837.
DR   PDB; 6MMK; EM; 6.08 A; B/D=1-837.
DR   PDB; 6MML; EM; 7.14 A; B/D=1-837.
DR   PDB; 6MMM; EM; 6.84 A; B/D=1-837.
DR   PDB; 6MMN; EM; 7.51 A; B/D=1-837.
DR   PDB; 6MMP; EM; 6.88 A; B/D=1-837.
DR   PDB; 6MMR; EM; 5.13 A; B/D=1-837.
DR   PDB; 6MMS; EM; 5.38 A; B/D=1-837.
DR   PDB; 6MMT; EM; 7.46 A; B/D=1-837.
DR   PDB; 6MMU; EM; 5.30 A; B/D=1-837.
DR   PDB; 6MMV; EM; 4.71 A; B/D=1-800.
DR   PDB; 6MMW; EM; 6.20 A; B/D=1-837.
DR   PDB; 6MMX; EM; 6.99 A; B/D=1-837.
DR   PDB; 6ODL; X-ray; 2.30 A; A/B=404-539, A/B=661-801.
DR   PDB; 6OVD; X-ray; 2.10 A; B=402-539, B=661-802.
DR   PDB; 6OVE; X-ray; 2.00 A; B=402-539, B=568-801.
DR   PDB; 6USU; X-ray; 2.09 A; B=402-539, B=661-802.
DR   PDB; 6USV; X-ray; 2.30 A; B=402-539, B=661-802.
DR   PDB; 6UZ6; X-ray; 1.66 A; B=402-539, B=661-800.
DR   PDB; 6UZG; X-ray; 1.94 A; B=402-539, B=661-802.
DR   PDB; 6UZR; X-ray; 1.87 A; B=402-539, B=661-802.
DR   PDB; 6UZW; X-ray; 2.13 A; B=402-539, B=661-802.
DR   PDB; 6UZX; X-ray; 2.41 A; B=402-539, B=661-802.
DR   PDB; 8JF7; EM; 7.73 A; B=1-842.
DR   PDBsum; 2A5S; -.
DR   PDBsum; 2A5T; -.
DR   PDBsum; 4JWX; -.
DR   PDBsum; 4NF4; -.
DR   PDBsum; 4NF5; -.
DR   PDBsum; 4NF6; -.
DR   PDBsum; 4NF8; -.
DR   PDBsum; 5DEX; -.
DR   PDBsum; 5I56; -.
DR   PDBsum; 5I57; -.
DR   PDBsum; 5I58; -.
DR   PDBsum; 5I59; -.
DR   PDBsum; 5JTY; -.
DR   PDBsum; 5TPW; -.
DR   PDBsum; 5TQ0; -.
DR   PDBsum; 5TQ2; -.
DR   PDBsum; 5U8C; -.
DR   PDBsum; 5VIH; -.
DR   PDBsum; 5VII; -.
DR   PDBsum; 5VIJ; -.
DR   PDBsum; 6MM9; -.
DR   PDBsum; 6MMA; -.
DR   PDBsum; 6MMB; -.
DR   PDBsum; 6MMG; -.
DR   PDBsum; 6MMH; -.
DR   PDBsum; 6MMI; -.
DR   PDBsum; 6MMJ; -.
DR   PDBsum; 6MMK; -.
DR   PDBsum; 6MML; -.
DR   PDBsum; 6MMM; -.
DR   PDBsum; 6MMN; -.
DR   PDBsum; 6MMP; -.
DR   PDBsum; 6MMR; -.
DR   PDBsum; 6MMS; -.
DR   PDBsum; 6MMT; -.
DR   PDBsum; 6MMU; -.
DR   PDBsum; 6MMV; -.
DR   PDBsum; 6MMW; -.
DR   PDBsum; 6MMX; -.
DR   PDBsum; 6ODL; -.
DR   PDBsum; 6OVD; -.
DR   PDBsum; 6OVE; -.
DR   PDBsum; 6USU; -.
DR   PDBsum; 6USV; -.
DR   PDBsum; 6UZ6; -.
DR   PDBsum; 6UZG; -.
DR   PDBsum; 6UZR; -.
DR   PDBsum; 6UZW; -.
DR   PDBsum; 6UZX; -.
DR   PDBsum; 8JF7; -.
DR   AlphaFoldDB; Q00959; -.
DR   EMDB; EMD-9147; -.
DR   EMDB; EMD-9148; -.
DR   EMDB; EMD-9149; -.
DR   EMDB; EMD-9150; -.
DR   EMDB; EMD-9151; -.
DR   EMDB; EMD-9152; -.
DR   EMDB; EMD-9153; -.
DR   EMDB; EMD-9154; -.
DR   EMDB; EMD-9155; -.
DR   EMDB; EMD-9156; -.
DR   EMDB; EMD-9157; -.
DR   EMDB; EMD-9158; -.
DR   EMDB; EMD-9159; -.
DR   EMDB; EMD-9160; -.
DR   EMDB; EMD-9161; -.
DR   EMDB; EMD-9162; -.
DR   EMDB; EMD-9163; -.
DR   EMDB; EMD-9164; -.
DR   EMDB; EMD-9165; -.
DR   SMR; Q00959; -.
DR   BioGRID; 246574; 21.
DR   ComplexPortal; CPX-283; NMDA receptor complex, GluN1-GluN2A.
DR   ComplexPortal; CPX-295; NMDA receptor complex, GluN1-GluN2A-GluN2B.
DR   CORUM; Q00959; -.
DR   DIP; DIP-34031N; -.
DR   IntAct; Q00959; 8.
DR   MINT; Q00959; -.
DR   STRING; 10116.ENSRNOP00000042235; -.
DR   BindingDB; Q00959; -.
DR   ChEMBL; CHEMBL310; -.
DR   DrugCentral; Q00959; -.
DR   GuidetoPHARMACOLOGY; 456; -.
DR   TCDB; 1.A.10.1.6; the glutamate-gated ion channel (gic) family of neurotransmitter receptors.
DR   GlyCosmos; Q00959; 7 sites, 2 glycans.
DR   GlyGen; Q00959; 7 sites, 2 N-linked glycans (2 sites).
DR   iPTMnet; Q00959; -.
DR   PhosphoSitePlus; Q00959; -.
DR   SwissPalm; Q00959; -.
DR   PaxDb; 10116-ENSRNOP00000042235; -.
DR   ABCD; Q00959; 2 sequenced antibodies.
DR   GeneID; 24409; -.
DR   KEGG; rno:24409; -.
DR   UCSC; RGD:2737; rat.
DR   AGR; RGD:2737; -.
DR   CTD; 2903; -.
DR   RGD; 2737; Grin2a.
DR   eggNOG; KOG1053; Eukaryota.
DR   InParanoid; Q00959; -.
DR   OrthoDB; 1034721at2759; -.
DR   PhylomeDB; Q00959; -.
DR   Reactome; R-RNO-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-RNO-8849932; Synaptic adhesion-like molecules.
DR   Reactome; R-RNO-9609736; Assembly and cell surface presentation of NMDA receptors.
DR   EvolutionaryTrace; Q00959; -.
DR   PRO; PR:Q00959; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0032590; C:dendrite membrane; IDA:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0098688; C:parallel fiber to Purkinje cell synapse; IDA:SynGO.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; ISO:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:UniProtKB.
DR   GO; GO:0098839; C:postsynaptic density membrane; ISO:RGD.
DR   GO; GO:0099092; C:postsynaptic density, intracellular component; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; ISO:RGD.
DR   GO; GO:0097060; C:synaptic membrane; ISO:RGD.
DR   GO; GO:0008021; C:synaptic vesicle; ISO:RGD.
DR   GO; GO:0043195; C:terminal bouton; IDA:RGD.
DR   GO; GO:0051117; F:ATPase binding; IPI:RGD.
DR   GO; GO:0005262; F:calcium channel activity; ISO:RGD.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IPI:RGD.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:RGD.
DR   GO; GO:0016595; F:glutamate binding; IDA:RGD.
DR   GO; GO:0035254; F:glutamate receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0022849; F:glutamate-gated calcium ion channel activity; ISS:UniProtKB.
DR   GO; GO:0004970; F:glutamate-gated receptor activity; IDA:RGD.
DR   GO; GO:0099507; F:ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0005261; F:monoatomic cation channel activity; ISO:RGD.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:RGD.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0022843; F:voltage-gated monoatomic cation channel activity; IMP:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IDA:RGD.
DR   GO; GO:0001508; P:action potential; IMP:RGD.
DR   GO; GO:0097553; P:calcium ion transmembrane import into cytosol; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IMP:RGD.
DR   GO; GO:0071359; P:cellular response to dsRNA; IEP:RGD.
DR   GO; GO:1905430; P:cellular response to glycine; IEP:RGD.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEP:RGD.
DR   GO; GO:0071396; P:cellular response to lipid; IEP:RGD.
DR   GO; GO:0071286; P:cellular response to magnesium ion; IEP:RGD.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEP:RGD.
DR   GO; GO:0071294; P:cellular response to zinc ion; IMP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0007268; P:chemical synaptic transmission; IMP:RGD.
DR   GO; GO:1990708; P:conditioned place preference; IEP:RGD.
DR   GO; GO:0097061; P:dendritic spine organization; IMP:UniProtKB.
DR   GO; GO:0033058; P:directional locomotion; ISO:RGD.
DR   GO; GO:0042417; P:dopamine metabolic process; ISO:RGD.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IMP:RGD.
DR   GO; GO:0007215; P:glutamate receptor signaling pathway; ISO:RGD.
DR   GO; GO:0021766; P:hippocampus development; IEP:RGD.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IDA:RGD.
DR   GO; GO:0007612; P:learning; ISO:RGD.
DR   GO; GO:0007611; P:learning or memory; ISO:RGD.
DR   GO; GO:0040011; P:locomotion; ISO:RGD.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEP:RGD.
DR   GO; GO:0007613; P:memory; IDA:UniProtKB.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0098815; P:modulation of excitatory postsynaptic potential; IMP:RGD.
DR   GO; GO:0098655; P:monoatomic cation transmembrane transport; IDA:ComplexPortal.
DR   GO; GO:0033555; P:multicellular organismal response to stress; IEP:RGD.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; ISO:RGD.
DR   GO; GO:0022008; P:neurogenesis; ISO:RGD.
DR   GO; GO:0048666; P:neuron development; IEP:RGD.
DR   GO; GO:0099646; P:neurotransmitter receptor transport, plasma membrane to endosome; IMP:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:RGD.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IDA:BHF-UCL.
DR   GO; GO:0097151; P:positive regulation of inhibitory postsynaptic potential; IMP:RGD.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:RGD.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IDA:ComplexPortal.
DR   GO; GO:0030163; P:protein catabolic process; ISO:RGD.
DR   GO; GO:1903539; P:protein localization to postsynaptic membrane; ISO:RGD.
DR   GO; GO:0001881; P:receptor recycling; IMP:RGD.
DR   GO; GO:0032012; P:regulation of ARF protein signal transduction; IGI:RGD.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IMP:RGD.
DR   GO; GO:0042391; P:regulation of membrane potential; IMP:RGD.
DR   GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; IDA:ComplexPortal.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; NAS:ComplexPortal.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; IMP:UniProtKB.
DR   GO; GO:0060078; P:regulation of postsynaptic membrane potential; ISO:RGD.
DR   GO; GO:1901419; P:regulation of response to alcohol; IEP:RGD.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   GO; GO:0014075; P:response to amine; IEP:RGD.
DR   GO; GO:0060359; P:response to ammonium ion; IEP:RGD.
DR   GO; GO:0001975; P:response to amphetamine; ISO:RGD.
DR   GO; GO:0051592; P:response to calcium ion; IEP:RGD.
DR   GO; GO:0009743; P:response to carbohydrate; IEP:RGD.
DR   GO; GO:0042220; P:response to cocaine; IEP:RGD.
DR   GO; GO:0090648; P:response to environmental enrichment; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IMP:ARUK-UCL.
DR   GO; GO:0060992; P:response to fungicide; IEP:RGD.
DR   GO; GO:1904880; P:response to hydrogen sulfide; IEP:RGD.
DR   GO; GO:0009416; P:response to light stimulus; IEP:RGD.
DR   GO; GO:0010226; P:response to lithium ion; IDA:RGD.
DR   GO; GO:0010042; P:response to manganese ion; IEP:RGD.
DR   GO; GO:0051597; P:response to methylmercury; IEP:RGD.
DR   GO; GO:0035094; P:response to nicotine; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0051707; P:response to other organism; IEP:RGD.
DR   GO; GO:0009611; P:response to wounding; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0048511; P:rhythmic process; IDA:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; ISO:RGD.
DR   GO; GO:0042428; P:serotonin metabolic process; ISO:RGD.
DR   GO; GO:0030431; P:sleep; ISO:RGD.
DR   GO; GO:0021510; P:spinal cord development; IEP:RGD.
DR   GO; GO:0001964; P:startle response; ISO:RGD.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0008542; P:visual learning; ISO:RGD.
DR   CDD; cd06378; PBP1_iGluR_NMDA_NR2; 1.
DR   CDD; cd13718; PBP2_iGluR_NMDA_Nr2; 1.
DR   Gene3D; 3.40.50.2300; -; 2.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 2.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_Glu_rcpt_met.
DR   InterPro; IPR015683; Ionotropic_Glu_rcpt.
DR   InterPro; IPR001320; Iontro_rcpt_C.
DR   InterPro; IPR018884; NMDAR2_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   PANTHER; PTHR18966:SF407; GLUTAMATE RECEPTOR IONOTROPIC, NMDA 2A; 1.
DR   PANTHER; PTHR18966; IONOTROPIC GLUTAMATE RECEPTOR; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   Pfam; PF10565; NMDAR2_C; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; Periplasmic binding protein-like I; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Cell projection; Cytoplasmic vesicle;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Magnesium; Membrane; Metal-binding;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Signal; Synapse; Transmembrane; Transmembrane helix; Transport; Zinc.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000255"
FT   CHAIN           23..1464
FT                   /note="Glutamate receptor ionotropic, NMDA 2A"
FT                   /id="PRO_0000011576"
FT   TOPO_DOM        23..555
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        556..576
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:B7ZSK1"
FT   TOPO_DOM        577..600
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   INTRAMEM        601..620
FT                   /note="Discontinuously helical"
FT                   /evidence="ECO:0000250|UniProtKB:B7ZSK1"
FT   TOPO_DOM        621..625
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        626..645
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:B7ZSK1"
FT   TOPO_DOM        646..816
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        817..837
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:B7ZSK1"
FT   TOPO_DOM        838..1464
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REGION          599..620
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:B7ZSK1"
FT   REGION          989..1083
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1462..1464
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000305"
FT   COMPBIAS        989..1008
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1019..1034
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1035..1083
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         44
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:27916457,
FT                   ECO:0007744|PDB:5TPW"
FT   BINDING         128
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:27916457,
FT                   ECO:0007744|PDB:5TPW"
FT   BINDING         266
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:27916457,
FT                   ECO:0007744|PDB:5TPW"
FT   BINDING         282
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000269|PubMed:27916457,
FT                   ECO:0007744|PDB:5TPW"
FT   BINDING         511..513
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0007744|PDB:2A5S, ECO:0007744|PDB:2A5T,
FT                   ECO:0007744|PDB:4NF4, ECO:0007744|PDB:4NF8,
FT                   ECO:0007744|PDB:5I56, ECO:0007744|PDB:5I57,
FT                   ECO:0007744|PDB:5I58, ECO:0007744|PDB:5I59,
FT                   ECO:0007744|PDB:5JTY"
FT   BINDING         518
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0000269|PubMed:24462099, ECO:0000269|PubMed:27618671,
FT                   ECO:0007744|PDB:2A5S, ECO:0007744|PDB:2A5T,
FT                   ECO:0007744|PDB:4NF4, ECO:0007744|PDB:4NF8,
FT                   ECO:0007744|PDB:5I56, ECO:0007744|PDB:5I57,
FT                   ECO:0007744|PDB:5I58, ECO:0007744|PDB:5I59,
FT                   ECO:0007744|PDB:5JTY"
FT   BINDING         689..690
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0000269|PubMed:24462099, ECO:0007744|PDB:2A5S,
FT                   ECO:0007744|PDB:2A5T, ECO:0007744|PDB:4NF4,
FT                   ECO:0007744|PDB:4NF8"
FT   BINDING         730..731
FT                   /ligand="L-glutamate"
FT                   /ligand_id="ChEBI:CHEBI:29985"
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0000269|PubMed:24462099, ECO:0007744|PDB:2A5S,
FT                   ECO:0007744|PDB:2A5T, ECO:0007744|PDB:4NF4,
FT                   ECO:0007744|PDB:4NF8"
FT   SITE            614
FT                   /note="Functional determinant of NMDA receptors"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         882
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         890
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         929
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1025
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1059
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1062
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1198
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1291
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        340
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        443
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        444
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        541
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        687
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        87..320
FT                   /evidence="ECO:0000269|PubMed:27916457,
FT                   ECO:0007744|PDB:5TPW, ECO:0007744|PDB:5TQ0,
FT                   ECO:0007744|PDB:5TQ2"
FT   DISULFID        429..455
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0000269|PubMed:24462099, ECO:0000269|PubMed:27618671,
FT                   ECO:0000269|PubMed:28468946, ECO:0000269|PubMed:28760974,
FT                   ECO:0000269|Ref.27, ECO:0007744|PDB:2A5S,
FT                   ECO:0007744|PDB:2A5T, ECO:0007744|PDB:4JWX,
FT                   ECO:0007744|PDB:4NF4, ECO:0007744|PDB:4NF5,
FT                   ECO:0007744|PDB:4NF6, ECO:0007744|PDB:4NF8,
FT                   ECO:0007744|PDB:5DEX, ECO:0007744|PDB:5I56,
FT                   ECO:0007744|PDB:5I57, ECO:0007744|PDB:5I58,
FT                   ECO:0007744|PDB:5I59, ECO:0007744|PDB:5JTY,
FT                   ECO:0007744|PDB:5U8C, ECO:0007744|PDB:5VIH,
FT                   ECO:0007744|PDB:5VII, ECO:0007744|PDB:5VIJ"
FT   DISULFID        436..456
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0000269|PubMed:23625947, ECO:0000269|PubMed:24462099,
FT                   ECO:0000269|PubMed:27618671, ECO:0000269|PubMed:28468946,
FT                   ECO:0000269|PubMed:28760974, ECO:0007744|PDB:2A5S,
FT                   ECO:0007744|PDB:2A5T, ECO:0007744|PDB:4JWX,
FT                   ECO:0007744|PDB:4NF4, ECO:0007744|PDB:4NF5,
FT                   ECO:0007744|PDB:4NF6, ECO:0007744|PDB:4NF8,
FT                   ECO:0007744|PDB:5DEX, ECO:0007744|PDB:5I56,
FT                   ECO:0007744|PDB:5I57, ECO:0007744|PDB:5I58,
FT                   ECO:0007744|PDB:5I59, ECO:0007744|PDB:5JTY,
FT                   ECO:0007744|PDB:5U8C, ECO:0007744|PDB:5VIH,
FT                   ECO:0007744|PDB:5VII, ECO:0007744|PDB:5VIJ"
FT   DISULFID        745..800
FT                   /evidence="ECO:0000269|PubMed:16281028,
FT                   ECO:0000269|PubMed:23625947, ECO:0000269|PubMed:24462099,
FT                   ECO:0000269|PubMed:28468946, ECO:0007744|PDB:2A5S,
FT                   ECO:0007744|PDB:2A5T, ECO:0007744|PDB:4JWX,
FT                   ECO:0007744|PDB:4NF4, ECO:0007744|PDB:4NF5,
FT                   ECO:0007744|PDB:4NF6, ECO:0007744|PDB:4NF8,
FT                   ECO:0007744|PDB:5U8C"
FT   MUTAGEN         233
FT                   /note="K->A,R: Nearly abolishes inhibition by Zn(2+)."
FT                   /evidence="ECO:0000269|PubMed:27916457"
FT   MUTAGEN         264
FT                   /note="N->W: Nearly abolishes inhibition by Zn(2+)."
FT                   /evidence="ECO:0000269|PubMed:27916457"
FT   MUTAGEN         282
FT                   /note="D->A,H: Nearly abolishes inhibition by Zn(2+)."
FT                   /evidence="ECO:0000269|PubMed:27916457"
FT   MUTAGEN         416
FT                   /note="F->A: Decreased sensitivity to glutamate."
FT                   /evidence="ECO:0000269|PubMed:24462099"
FT   MUTAGEN         730
FT                   /note="Y->F,L,M: Strongly decreased sensitivity to
FT                   glutamate."
FT                   /evidence="ECO:0000269|PubMed:24462099"
FT   MUTAGEN         734
FT                   /note="V->A: Decreased sensitivity to glutamate."
FT                   /evidence="ECO:0000269|PubMed:24462099"
FT   CONFLICT        246
FT                   /note="L -> F (in Ref. 3; BAA02498)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        758
FT                   /note="S -> T (in Ref. 3; BAA02498 and 4; AAB58801)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        990
FT                   /note="E -> D (in Ref. 4; AAB58801)"
FT                   /evidence="ECO:0000305"
FT   STRAND          35..40
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          68..73
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           79..91
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          96..101
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           108..120
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          124..128
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           129..132
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          144..147
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           151..164
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          169..177
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           180..193
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          194..196
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          198..200
FT                   /evidence="ECO:0007829|PDB:5TPW"
FT   STRAND          204..207
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           213..219
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          225..230
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           233..245
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   TURN            247..249
FT                   /evidence="ECO:0007829|PDB:5TQ2"
FT   STRAND          253..257
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           259..262
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          277..281
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          284..286
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           288..309
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          310..312
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   TURN            335..337
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          338..340
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          341..343
FT                   /evidence="ECO:0007829|PDB:5TQ2"
FT   STRAND          346..348
FT                   /evidence="ECO:0007829|PDB:5TQ2"
FT   STRAND          354..358
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   STRAND          362..366
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   TURN            368..370
FT                   /evidence="ECO:0007829|PDB:5TPW"
FT   STRAND          372..377
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   TURN            379..382
FT                   /evidence="ECO:0007829|PDB:5TQ0"
FT   HELIX           402..404
FT                   /evidence="ECO:0007829|PDB:5U8C"
FT   STRAND          406..410
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   TURN            414..416
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          417..421
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   TURN            424..426
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          434..447
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          449..458
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           459..471
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          475..479
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          482..485
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          488..491
FT                   /evidence="ECO:0007829|PDB:5I58"
FT   HELIX           495..501
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          506..508
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           516..519
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          522..524
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          529..531
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          533..538
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           668..671
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           673..675
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          676..678
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          686..688
FT                   /evidence="ECO:0007829|PDB:6UZW"
FT   HELIX           689..697
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           699..705
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           706..708
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           713..721
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          726..731
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           732..740
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           743..745
FT                   /evidence="ECO:0007829|PDB:5VII"
FT   STRAND          747..751
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           752..754
FT                   /evidence="ECO:0007829|PDB:5U8C"
FT   HELIX           755..757
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          759..761
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   STRAND          764..766
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           772..784
FT                   /evidence="ECO:0007829|PDB:4JWX"
FT   HELIX           787..795
FT                   /evidence="ECO:0007829|PDB:4JWX"
SQ   SEQUENCE   1464 AA;  165469 MW;  DC1528E1898DECA4 CRC64;
     MGRLGYWTLL VLPALLVWRD PAQNAAAEKG PPALNIAVLL GHSHDVTERE LRNLWGPEQA
     TGLPLDVNVV ALLMNRTDPK SLITHVCDLM SGARIHGLVF GDDTDQEAVA QMLDFISSQT
     FIPILGIHGG ASMIMADKDP TSTFFQFGAS IQQQATVMLK IMQDYDWHVF SLVTTIFPGY
     RDFISFIKTT VDNSFVGWDM QNVITLDTSF EDAKTQVQLK KIHSSVILLY CSKDEAVLIL
     SEARSLGLTG YDFFWIVPSL VSGNTELIPK EFPSGLISVS YDDWDYSLEA RVRDGLGILT
     TAASSMLEKF SYIPEAKASC YGQAEKPETP LHTLHQFMVN VTWDGKDLSF TEEGYQVHPR
     LVVIVLNKDR EWEKVGKWEN QTLSLRHAVW PRYKSFSDCE PDDNHLSIVT LEEAPFVIVE
     DIDPLTETCV RNTVPCRKFV KINNSTNEGM NVKKCCKGFC IDILKKLSRT VKFTYDLYLV
     TNGKHGKKVN NVWNGMIGEV VYQRAVMAVG SLTINEERSE VVDFSVPFVE TGISVMVSRS
     NGTVSPSAFL EPFSASVWVM MFVMLLIVSA IAVFVFEYFS PVGYNRNLAK GKAPHGPSFT
     IGKAIWLLWG LVFNNSVPVQ NPKGTTSKIM VSVWAFFAVI FLASYTANLA AFMIQEEFVD
     QVTGLSDKKF QRPHDYSPPF RFGTVPNGST ERNIRNNYPY MHQYMTRFNQ RGVEDALVSL
     KTGKLDAFIY DAAVLNYKAG RDEGCKLVTI GSGYIFASTG YGIALQKGSP WKRQIDLALL
     QFVGDGEMEE LETLWLTGIC HNEKNEVMSS QLDIDNMAGV FYMLAAAMAL SLITFIWEHL
     FYWKLRFCFT GVCSDRPGLL FSISRGIYSC IHGVHIEEKK KSPDFNLTGS QSNMLKLLRS
     AKNISNMSNM NSSRMDSPKR ATDFIQRGSL IVDMVSDKGN LIYSDNRSFQ GKDSIFGDNM
     NELQTFVANR HKDNLSNYVF QGQHPLTLNE SNPNTVEVAV STESKGNSRP RQLWKKSMES
     LRQDSLNQNP VSQRDEKTAE NRTHSLKSPR YLPEEVAHSD ISETSSRATC HREPDNNKNH
     KTKDNFKRSM ASKYPKDCSD VDRTYMKTKA SSPRDKIYTI DGEKEPSFHL DPPQFVENIT
     LPENVGFPDT YQDHNENFRK GDSTLPMNRN PLHNEDGLPN NDQYKLYAKH FTLKDKGSPH
     SEGSDRYRQN STHCRSCLSN LPTYSGHFTM RSPFKCDACL RMGNLYDIDE DQMLQETGNP
     ATREEVYQQD WSQNNALQFQ KNKLRINRQH SYDNILDKPR EIDLSRPSRS ISLKDRERLL
     EGNLYGSLFS VPSSKLLGNK SSLFPQGLED SKRSKSLLPD HASDNPFLHT YGDDQRLVIG
     RCPSDPYKHS LPSQAVNDSY LRSSLRSTAS YCSRDSRGHS DVYISEHVMP YAANKNTMYS
     TPRVLNSCSN RRVYKKMPSI ESDV
//
